Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study-Reference-Cited by-同舟云学术

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Published:2018-02 Issue:2 Volume:19 Page:216-228
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

DiNardo Courtney D,Pratz Keith W,Letai Anthony,Jonas Brian A,Wei Andrew H,Thirman Michael,Arellano Martha,Frattini Mark G,Kantarjian Hagop,Popovic Relja,Chyla Brenda,Xu Tu,Dunbar Martin,Agarwal Suresh K,Humerickhouse Rod,Mabry Mack,Potluri Jalaja,Konopleva Marina,Pollyea Daniel A

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. The treatment of elderly patients with acute myeloid leukemia;Krug;Dtsch Arztebl Int,2011

2. Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies;Pettit;Front Oncol,2015

3. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia;Kantarjian;Blood,2010

4. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome;Kantarjian;Cancer,2006

5. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells;Lagadinou;Cell Stem Cell,2013

Cited by 560 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia;Leukemia Research;2024-10

2. Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis;Leukemia & Lymphoma;2024-09-05

3. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia;Leukemia Research;2024-09

4. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study;Annals of Hematology;2024-08-29

5. TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells;Nature Communications;2024-08-28